

## **EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer"**

From 15 October (afternoon) to 17 October 2009  
with a tutorial on 14 October, and 15 October (morning)

*Crowne Plaza City Centre "Le Palace", 3 rue Gineste, 1210 Brussels, Belgium*

### **PROGRAM**

#### **SESSION 3**

**Friday 16 October 2009 (afternoon)**

#### **TOPIC 5 (13h30 – 15h30)**

*New assessment criteria for clinico-genomic trials*

Chairs: Roger Stupp (EU) & Larry Rubinstein (US)

<b>Molecular imaging</b>	P. Flamen
<b>Methodology and design of phase 0 and phase 2 trials with biomarker variables and endpoints</b>	L. Rubinstein
<b>Validation of statistically reliable biomarkers</b>	M. Buyse
<b>New targets and cancer therapy: successes and failures</b>	J. Dancey

#### **TOPIC 6 (16h00 – 18h00)**

*Can we obtain the most from the least tissue?*

Chairs: Manfred Schmitt (EU) & David Rimm (US)

<b>Getting the most from the least tissue</b>	P. Mack
<b>Beyond IHC: Accurate, reproducible and quantitative measurement of protein analyte concentrations in fixed tissue</b>	D. Rimm
<b>Optimizing Information Obtained from Fine Needle Aspiration (FNA) Biopsies</b>	D. Clark
<b>Emerging tissue-based cancer biomarkers in breast cancer</b>	M. Schmitt
<b>Selected abstract for oral presentation (abs. #125): Downregulation of EZH2 is associated with estrogen receptor upregulation and favourable outcome to tamoxifen in advanced breast cancer</b>	E. Reijm